North America severe asthma market is set for growth, driven by high asthma prevalence, increased awareness, and advanced treatment options for severe cases. Ankush Nikam Future Market Insights, Inc.

The key is a drug originally designed to treat asthma patients. "The way that omalizumab, brand name Xolair, works is that it binds to your allergy cells, and it takes it out of circulation ...

The ability of four different asthma assessment tools to predict each of five adverse clinical asthma outcomes was modeled using both logistic regression and CART analysis using data collected for ...

Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase III drugs for Chronic Obstructive Pulmonary ...

Perspective from Michael E. Wechsler, MD, MMSc Dupilumab was more effective than omalizumab, benralizumab and mepolizumab in treating patients with severe asthma, according to a pair of abstracts ...

The results of these three placebo-controlled randomized studies demonstrate that mepolizumab is efficacious ... in the production of this manuscript. Omalizumab reduces exacerbations, improves ...

(RTTNews) - Researchers at King's College London have found a new treatment for asthma attacks, which could be a "game-changer" for the patients. Lead investigator Prof Mona Bafadhel, of King's ...

Fasenra, otherwise known as benralizumab, is used to treat adult ... which compared the drug to the only approved EGPA treatment, mepolizumab, in patients with relapsing or refractory EGPA.